Answers are grounded in this paper and cite their sources.
Unique case shows bimekizumab significantly improves chronic alopecia in a male patient, highlighting treatment potential.
Sycosis barbae (SB) is a chronic, potentially scarring alopecia that primarily affects the beard. We report a unique case of refractory SB in a 31‐year‐old male successfully treated with bimekizumab, a dual inhibitor of interleukin (IL)‐17A and IL‐17F. Significant clinical improvement was observed after the second injection, with complete remission achieved after 4 months, highlighting the potential of this novel therapeutic approach for SB.
No takes yet. Share an insight, caveat, or question.
Madanchi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: